

Clinical Updates from San Antonio
Clinical Update #1: HR+/HER2- Breast Cancer: CDK4/6 Inhibitors

References

Tweet 2

Gnant M, Dueck AC, Frantal S, et al. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). *J Clin Oncol*. 2022;40(3):282-293. doi:10.1200/JCO.21.02554

Harbeck N, Ragosti P, Shahir A, Johnston S, O'Shaughnessy J. Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'. *Ann Oncol*. 2022;33(2):227-228. doi:10.1016/j.annonc.2021.10.015

Johnston S, Toi M, O'Shaughnessy J, et al. SABCS 2022. Abstract GS1-09. <https://www.sabcs.org/Portals/SABCS2016/2022%20SABCS/Tuesday.pdf?ver=2022-11-21-163822-377>

Johnston SRD, Toi M, O'Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2022. doi:10.1016/S1470-2045(22)00694-5

Rugo HS, O'Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. *Ann Oncol*. 2022;33(6):616-627. doi:10.1016/j.annonc.2022.03.006

Toi M, Boyle F, Young-Hyuck I, et al. Adjuvant abemaciclib combined with endocrine therapy: efficacy results in monarchE Cohort 1. *Oncologist*. 2022. doi:10.1093/oncolo/oyac234

Glossary

1L, first line
aBC, advanced breast cancer
AE, adverse event
BID, twice daily
CBR, clinical benefit rate
CDK4/6, cyclin dependent kinase 4/6
CI, confidence interval
DRFS, distant relapse-free survival
EBC, early breast cancer
ECOG, Eastern Cooperative Oncology Group
ET, endocrine therapy
HER2, human epidermal growth factor receptor 2
HR, hazard ratio
HR+, hormone receptor positive
i, inhibitor

IDFS, invasive disease-free survival
mBC, metastatic breast cancer
mOS, median overall survival
mPFS, median progression-free survival
N+, lymph node positive
OR, odds ratio
ORR, objective response rate
OS, overall survival
pALN, positive axillary lymph nodes
PS, performance status
w/, with